By Bhanvi Satija and Christy Santhosh (Reuters) -Websites selling compounded versions of popular weight-loss drugs from Novo ...

Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...

A recent study reveals many websites selling compounded versions of weight-loss drugs do not inform users of risks, often ...

Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do ...

Current laws and regulations are not enough to protect Americans from the risks of compounded versions of popular weight loss ...

The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare ...

Eli Lilly & Co. ( LLY) thinks its next experimental weight-loss pill could get approved as soon as early 2026.

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...

Zyn gains cult status among Gen Z, praised for boosting workouts, alertness, and dubbed O-Zyn-pic for weight loss.

This practice is not approved by the U.S. Food and Drug Administration (FDA). "Health care clinicians do not typically ... a ...